This site is intended for U.S. Health Care Professionals
Oncology News features editorially independent news content provided by MDLinx. Pfizer does not influence and is not involved with the selection of content in this section.
| Subtype and pathway specific responses to anticancer compounds in breast cancer Heiser LM et al. Collections of breast cancer cell lines mirror many of the molecular subtypes and.. | Thu, 23 Feb 2012 | |
| Defibrotide for prophylaxis of hepatic veno-occlusive disease in pediatric hemopoietic stem-cell transplantation: An open-label, phase 3, randomized controlled trial Corbacioglu S et al. Defibrotide prophylaxis seems to reduce incidence of veno-occlusive disease a.. | Thu, 23 Feb 2012 | |
| Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomization Fallowfield LJ et al. Clinical benefits of switching to exemestane are accompanied by good overal.. | Thu, 23 Feb 2012 | |
| Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review Liao X et al. Co-existence of PIK3CA (the PI3K p110alpha subunit) exon 9 and 20 mutations, but .. | Thu, 23 Feb 2012 | |
| Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: A long-term follow-up study Thomas S et al. This study shows that large tumors with disomy 3 have an increased risk to develop.. | Thu, 23 Feb 2012 | |
Click here to view more articles.
The article you selected will open in a new window, and you will be redirected to the publisher's web site. To return to Pfizer for Oncology Professionals, close the new window.
